Oerlikon (Germany)

ABSTRACT Digitally supported continuous improvement (CI) in manufacturing SMEs often stalls not because tools fail, but because governance decisions are made under low visibility, mixed signals, and uneven trace quality. Existing instruments can position an organization or report activity and outcomes, yet they rarely bind minimal, auditable evidence to an explicit next move. This paper introduces the Positioning and Governance Compass (PG‐Compass), a low‐burden decision overlay that converts a fixed Minimal Evidence Packet into exactly one risk‐aware governance move—ADVANCE, HOLD, REPAIR, or RESTART—paired with a short Decision Record for decision provenance. PG‐Compass enforces conservative defaults: it caps confidence and blocks escalation under severe credibility constraints (e.g., trace‐integrity/backfilling risk or control‐framing risk) and routes to HOLD/REPAIR when signals are incomplete or contradictory. The artifact is grounded in routine dynamics and socio‐technical thinking, treating routine–trace mismatches and off‐ledger work as governance‐relevant signals. Evaluation uses an independent multi‐rater protocol on transcript‐derived evidence packets (nine interview cases) to assess decision consistency and auditability, without making performance or outcome claims.

Leucine-rich repeat kinase 2 (LRRK2) belongs to the subfamily of tyrosine kinase-like kinases, the main function of which is to catalyze the transfer of γ-phosphate from ATP to the substrate in the cell due to the kinase domains. The exact functions of LRRK2 in the cell remain unknown. It has been shown that mutations in the LRRK2 gene, which are the cause of the development of the most common autosomal dominant form of neurodegenerative disease, Parkinson's disease (PD), mainly lead to a pathological increase in kinase activity. This review describes the structure of LRRK2 and the functional activity of LRRK2 kinase in the form of a monomer, dimer, and even a tetramer and describes the effect of mutations in the LRRK2 gene on the structure and kinase activity of the LRRK2 enzyme. Understanding the structure and functions of LRRK2 opens up new prospects for using it as a target for PD therapy.